CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and ...

SINGAPORE, June 16, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and ...

Cells of certain blood cancers such as Hodgkin’s lymphoma carry the protein CD30 on their surface. The molecule is not only an indicator of a few cancers of the immune system but also increases the ...

Figure 4: Combined analysis of CD30 expression and apoptosis in HES-2 serum replacement cultures by flow cytometry and inhibition of apoptosis by expression of CD30 variant. We also considered whether ...

A recent study explored the efficacy of brentuximab vedotin (BV) in patients with high-CD30–expressing non-Hodgkin lymphoma (NHL) to determine who is most likely to benefit. A recent study explored ...

Please provide your email address to receive an email when new articles are posted on . Since the discovery of the CD30 molecule in 1982, progress has been made in the treatment and survival outcomes ...

CD30 expression is characteristic of the malignant Reed-Sternberg cell in Hodgkin lymphoma (HL) and several other lymphoid malignancies, such as anaplastic large-cell lymphoma (ALCL). Although ...

Please provide your email address to receive an email when new articles are posted on . The introduction of rituximab in the 1990s revolutionized the treatment of CD20+ B-cell lymphomas. Unfortunately ...

SINGAPORE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and ...

The study, which was supported by the German Cancer Aid, suggests that vaccination against EBV might reduce the risk of developing Hodgkin's lymphoma. In addition, the study provides insights into new ...